Adil Daud, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Adil Daud, MD

HS Clinical Professor, Department of Medicine (Hematology/Oncology), UCSF; Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center

Phone: (415) 353-9900 (appts)
Box 1711, UCSF
San Francisco, CA 94143-1711

View on UCSF Profiles

Cancer Center Membership

Program Member » Developmental Therapeutics

Education

St. Francis De Sales College, Nagpur, India, 1980, HSC diploma in general science
Government Medical College, Nagpur, India, 1986, MBBS degree in Medicine


Professional Experience

  • 1987-1990
    Postdoctoral Fellow, Laboratory of F. Merlin Bumpus, PhD and Ahsan Husain, PhD, Cleveland Clinic Foundation, Cleveland, OH
  • 1990-1994
    Research Assistant Staff, Laboratory of Loren Field, PhD, Krannert Institute of Cardiology, Indiana University Medical Center, Indianapolis, IN
  • 1994-1997
    Internship and Residency in Internal Medicine, Indiana University Medical Center, Indianapolis, IN
  • 1997-2000
    Fellowship in Hematology/Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
  • 2000-2001
    Clinical Attending Physician, Developmental Chemotherapy, Memorial Sloan-Kettering Cancer Center, New York, NY
  • 2001-2005
    Assistant Professor, Cutaneous Oncology and GI Comprehensive Program, H. Lee Moffitt Cancer Center, Tampa, FL
  • 2006-2008
    Associate Professor, Cutaneous Oncology, GI and Experimental Therapeutics Program, H Lee Moffitt Cancer Center, Tampa, FL
  • 2006-2008
    Director, Moffitt Clinical Research Network
  • 2008-2010
    Clinical Associate Professor and Director, Melanoma Clinical Research, University of California, San Francisco, CA
  • 2010-present
    HS Clinical Professor of Medicine and Director, Melanoma Program, University of California, San Francisco, San Francisco CA

Honors & Awards

  • 1986
    Honors in Pediatrics, Government Medical College, Nagpur, India
  • 2000
    Young Investigator Award, American Society for Clinical Oncology for project “Regulation of mRNA stability by Elongation factor I.
  • 2005-2007
    Clinical Trial Award: Highest Number of Patients Enrolled in clinical trials at Moffitt Cancer Center
  • 2007-2010
    Best Doctors in America Award, Castle Connolly

Selected Publications

  1. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol. 2015 Nov 1; 151(11):1206-12.
    View on PubMed
  2. Nivolumab plus ipilimumab in the treatment of advanced melanoma. J Hematol Oncol. 2015; 8(1):123.
    View on PubMed
  3. Current and Emerging Perspectives on Immunotherapy for Melanoma. Semin Oncol. 2015 Dec; 42 Suppl 3:S3-S11.
    View on PubMed
  4. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015 Dec 1; 33(34):4023-31.
    View on PubMed
  5. Future of combination therapy with dabrafenib and trametinib in metastatic melanoma. Expert Opin Pharmacother. 2015 Oct; 16(14):2257-63.
    View on PubMed
  6. Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. Ann Oncol. 2015 Oct; 26(10):2173-9.
    View on PubMed
  7. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):908-18.
    View on PubMed
  8. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2015 Oct 1; 21(19):4286-93.
    View on PubMed
  9. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun 25; 372(26):2521-32.
    View on PubMed
  10. The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. Drugs. 2015 Apr; 75(6):563-75.
    View on PubMed
  11. The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. Br J Cancer. 2015 Apr 14; 112(8):1326-31.
    View on PubMed
  12. Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors. J Clin Oncol. 2015 Mar 20; 33(9):1060-6.
    View on PubMed
  13. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Ann Oncol. 2015 Feb; 26(2):415-21.
    View on PubMed
  14. PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother. 2014 Nov 2; 10(11):3111-6.
    View on PubMed
  15. Involution of Eruptive Melanocytic Nevi on Combination BRAF and MEK Inhibitor Therapy. JAMA Dermatol. 2014 Nov 1; 150(11):1209-12.
    View on PubMed
  16. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014 Dec; 71(6):1102-1109.e1.
    View on PubMed
  17. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014 Nov 10; 26(5):638-52.
    View on PubMed
  18. Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. J Clin Oncol. 2014 Nov 20; 32(33):3697-704.
    View on PubMed
  19. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014 Aug; 15(9):954-65.
    View on PubMed
  20. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20; 384(9948):1109-17.
    View on PubMed

Go to UCSF Profiles, powered by CTSI